Curcumol exhibits anti-inflammatory properties by interfering with the JNK-mediated AP-1 pathway in lipopolysaccharide-activated RAW264.7 cells

被引:57
作者
Chen, Xi [1 ,2 ]
Zong, Chuanjie [1 ,2 ,3 ]
Gao, Yuan [1 ,2 ]
Cai, Runlan [1 ,2 ]
Fang, Lei [1 ,2 ]
Lu, Juan [1 ,2 ]
Liu, Fen [1 ,2 ]
Qi, Yun [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Inst Med Plant Dev, Beijing 100193, Peoples R China
[2] Peking Union Med Coll, Beijing 100193, Peoples R China
[3] Heilongjiang Univ Chinese Med, Harbin 150040, Peoples R China
基金
中国国家自然科学基金;
关键词
Curcumol; Anti-inflammation; AP-1 (activator protein-1); JNK (c-Jun N-terminal kinase); Lipopolysaccharide (LPS); NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; GAS-CHROMATOGRAPHY; IN-VITRO; INNATE; CYCLOOXYGENASE-2; INHIBITION; EXPRESSION; MONOCYTE; IMMUNITY;
D O I
10.1016/j.ejphar.2013.11.007
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Curcumol is one of the major components of the essential oil of Rhizoma Curcumae, a common traditional Chinese medicine with anti-inflammatory properties. However, the anti-inflammatory activity and the underlying molecular mechanisms of this compound remain unclear. In the present study, the anti-inflammation effect of curcumol on lipopolysaccharide (LPS)-induced RAW264.7 cells is demonstrated along with its underlying mechanisms. We show that curcumol inhibits [PS-induced NO production by suppressing iNOS mRNA expression and protein level but not iNOS activity. Moreover, curcumol inhibits [PS-induced production of TNF-alpha, IL-1 beta and IL-6 at both the transcriptional and translational levels. Further investigations reveal that these effects mainly act via suppressing JNK-mediated AP-1 rather than the NF-kappa B pathway; these effects include a decrease in the phosphorylation level of JNK and a direct inhibition of the activity of p-JNK. These data provide scientific molecular evidence that curcumol may be a potential lead compound for a novel anti-inflammatory drug because of its inhibitory activity on the production of various inflammatory mediators. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:339 / 345
页数:7
相关论文
共 50 条
[1]
ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.iy.02.040184.001435
[2]
Adcock I M, 1997, Monaldi Arch Chest Dis, V52, P178
[3]
Effects of phosphatidylserine on p38 mitogen activated protein kinase, cyclic AMP responding element binding protein and nuclear factor-κB activation in resting and activated microglial cells [J].
Ajmone-Cat, MA ;
De Simone, R ;
Nicolini, A ;
Minghetti, L .
JOURNAL OF NEUROCHEMISTRY, 2003, 84 (02) :413-416
[4]
Cytokines and anti-cytokine biologicals in autoimmunity: present and future [J].
Andreakos, ET ;
Foxwell, BM ;
Brennan, FM ;
Maini, RN ;
Feldmann, M .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (4-5) :299-313
[5]
[Anonymous], INFLAMM ALLERGY, DOI [10.2174/1568010054022024, DOI 10.2174/1568010054022024]
[6]
Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production [J].
Bal-Price, A ;
Matthias, A ;
Brown, GC .
JOURNAL OF NEUROCHEMISTRY, 2002, 80 (01) :73-80
[7]
The two NF-κB activation pathways and their role in innate and adaptive immunity [J].
Bonizzi, G ;
Karin, M .
TRENDS IN IMMUNOLOGY, 2004, 25 (06) :280-288
[8]
8-Prenylkaempferol suppresses inducible nitric oxide synthase expression through interfering with JNK-mediated AP-1 pathway in murine macrophages [J].
Chen, Chien-Chih ;
Tsai, Pei-Chung ;
Wei, Bai-Luh ;
Chiou, Wen-Fei .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) :430-436
[9]
Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1β by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells [J].
Choi, Y. ;
Lee, M. K. ;
Lim, S. Y. ;
Sung, S. H. ;
Kim, Y. C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (06) :933-940
[10]
Modulation of acute and chronic inflammatory processes by a traditional medicine preparation GCSB-5 both in vitro and in vivo animal models [J].
Chung, Hwa-Jin ;
Lee, Hak-Sun ;
Shin, Joon-Shik ;
Lee, Sang-Ho ;
Park, Byung-Mo ;
Youn, You-Suk ;
Lee, Sang Kook .
JOURNAL OF ETHNOPHARMACOLOGY, 2010, 130 (03) :450-459